Aligning With the Right PBM: Why Medicare Star Ratings Matter

As member ratings, complaints and other experience measures play a greater role in the Medicare Star Rating program, having the right pharmacy benefit management team has become increasingly critical to health plan success.

BACKGROUND

In 2008, the Centers for Medicare and Medicaid Services (CMS) launched the Star Rating program to measure the quality of Medicare Part D Plans (PDP) and Medicare Advantage Plans (MAPD) and help Medicare beneficiaries make more informed decisions about the coverage they purchase.

PHARMACY QUALITY ALLIANCE AWARD: HIGH ACHIEVEMENT IN MEDICATION QUALITY MEASURES

On May 13, 2021, Navitus received the 2021 Pharmacy Quality Alliance (PQA) Laura Cranston Excellence in Quality Award for our prescription drug plan, Navitus MedicareRx. According to PQA, this award demonstrates Navitus’ exemplary management of medications for Medicare members and our commitment to high-quality medication use strategies to care for plan sponsors and their members.

This award goes to PDPs with at least a 4.5 Medicare Part D summary rating and a 4-star rating on all five PQA medication measures used within the 2021 CMS Star Ratings Program. In 2021, Navitus MedicareRx received a 4.5 out of 5 summary rating, making it Navitus’ third year to receive a Star Rating of 4.5 and our fifth year to rank higher than any other PBM-sponsored Medicare PDP Employer Group Waiver Plan. Navitus is one of nine health care organizations to receive PQA’s Excellence in Quality Award for PDPs this year, highlighting our industry-leading clinical programs that work together to address medication adherence.

UNDERSTANDING MEASUREMENT AND MANAGEMENT TOOLS TO CONTROL COSTS

Taking medications as prescribed is critical for improving member health outcomes and preventing unnecessary costs. However, medication non-adherence is a longstanding issue in the United States. In fact, according to the U.S. Food & Drug Administration, medications are not taken as prescribed 50% of the time.1 To help members navigate the complex medication journey, Navitus offers solutions designed to improve clinical outcomes, maximize interventions, reduce costs and provide the personalized support they need to stay adherent.

In this new era of performance, understanding how your PBM measures up in terms of quality is an essential starting point.

“The effective use of medications is a top issue for all care providers, and it is extremely important in the Medicare Part D program,” Micah Cost, PharmD, MS, chief executive officer at PQA said. “This year, PQA recognizes 16 plans for their exemplary management of medications for their Medicare members. The excellence and improvement recognized by these awards reflect the organizations’ commitment to high quality medication use strategies by the plans and their partners to care for patients.”

At Navitus, plan sponsors and their members are at the center of everything we do, and this dedication is reflected in our consistently exemplary Medicare quality measures.

LOOKING DEEPER: THE IMPORTANCE OF SUBCATEGORY RATINGS

Health plans and members should not only evaluate the overall Star Rating of their prescription drug plan, but they should also consider performance in the individual subcategories. In 2021, Navitus earned a rating of 4 Stars or higher in five categories:

Medication Adherence for Diabetes Medications

Medication Adherence for Hypertension (RAS antagonists)

Medication Adherence for Cholesterol (Statins)

MTM Program Completion Rate for CMR

Statin Use in Persons with Diabetes

WHAT THIS MEANS FOR PLAN SPONSORS

Medicare quality measures highlight a PBM’s commitment to helping members achieve the best health by managing their chronic conditions through effective, individualized services.

Best-in-class clinical care and superior customer service are foundational to our MedicareRx program. There are many factors that influence a member’s ability to adhere to their medications. As the pandemic continues to exacerbate these barriers to adherence, especially among the senior population, our consistently strong Star Ratings are just one of many indicators that demonstrate our ability to deliver high-touch services that lower costs and improve health outcomes.

Why You Need to Take Your Medications as Prescribed or Instructed. U.S. Food & Drug Administration. https://www.fda.gov/drugs/special-features/why-you-need-take-your-medications-prescribed-or-instructed. Updated February 16, 2016. Accessed May 20, 2021.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

PBM 101: Understanding Transparency for Better Pharmacy Benefits

PBM 101: Understanding Transparency for Better Pharmacy Benefits

When it comes to pharmacy benefit managers (PBMs), the word “transparency” gets thrown around a lot. It’s frequently promised, widely discussed and inconsistently delivered.  …

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

previous arrow
next arrow